ASCENDIS PHARMA A/S - ADR (ASND) Stock Price, Quote, News and Overview
NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD
ASND Quote, Performance and Key Statistics
152.43
-2.15 (-1.39%)
The current stock price of ASND is 152.43 USD. In the past month the price increased by 19.56%. In the past year, price decreased by -4.37%.
ASND Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ASND
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900 DK
CEO: Jan Moller Mikkelsen
Employees: 879
Company Website: https://ascendispharma.dk/
Investor Relations: https://investors.ascendispharma.com
Phone: 4570222244
ASCENDIS PHARMA A/S - ADR / ASND FAQ
What is the stock price of ASCENDIS PHARMA A/S - ADR today?
The current stock price of ASND is 152.43 USD. The price decreased by -1.39% in the last trading session.
What is the ticker symbol for ASCENDIS PHARMA A/S - ADR stock?
The exchange symbol of ASCENDIS PHARMA A/S - ADR is ASND and it is listed on the Nasdaq exchange.
On which exchange is ASND stock listed?
ASND stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ASCENDIS PHARMA A/S - ADR stock?
22 analysts have analysed ASND and the average price target is 207.06 USD. This implies a price increase of 35.84% is expected in the next year compared to the current price of 152.43. Check the ASCENDIS PHARMA A/S - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ASCENDIS PHARMA A/S - ADR worth?
ASCENDIS PHARMA A/S - ADR (ASND) has a market capitalization of 9.12B USD. This makes ASND a Mid Cap stock.
How many employees does ASCENDIS PHARMA A/S - ADR have?
ASCENDIS PHARMA A/S - ADR (ASND) currently has 879 employees.
What are the support and resistance levels for ASCENDIS PHARMA A/S - ADR (ASND) stock?
ASCENDIS PHARMA A/S - ADR (ASND) has a support level at 135.07. Check the full technical report for a detailed analysis of ASND support and resistance levels.
Is ASCENDIS PHARMA A/S - ADR (ASND) expected to grow?
The Revenue of ASCENDIS PHARMA A/S - ADR (ASND) is expected to grow by 79.11% in the next year. Check the estimates tab for more information on the ASND EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ASCENDIS PHARMA A/S - ADR (ASND) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ASND, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ASND, evaluating the profitability, health, valuation and growth aspects
- ASCENDIS PHARMA A/S - ADR (ASND) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ASCENDIS PHARMA A/S - ADR (ASND) Sales and EPS estimates to see what analysts future expectations are.
- ASCENDIS PHARMA A/S - ADR (ASND) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ASCENDIS PHARMA A/S - ADR (ASND) Insider and Institutional Ownership to learn about the owners and their transactions.
- ASCENDIS PHARMA A/S - ADR (ASND) Stock Chart to make your own analysis
- ASCENDIS PHARMA A/S - ADR (ASND) Latest news and press-releases to stay up to date.
Does ASCENDIS PHARMA A/S - ADR (ASND) stock pay dividends?
ASND does not pay a dividend.
When does ASCENDIS PHARMA A/S - ADR (ASND) report earnings?
ASCENDIS PHARMA A/S - ADR (ASND) will report earnings on 2025-04-30, after the market close.
What is the Price/Earnings (PE) ratio of ASCENDIS PHARMA A/S - ADR (ASND)?
ASCENDIS PHARMA A/S - ADR (ASND) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.88).
What is the Short Interest ratio of ASCENDIS PHARMA A/S - ADR (ASND) stock?
The outstanding short interest for ASCENDIS PHARMA A/S - ADR (ASND) is 5.55% of its float. Check the ownership tab for more information on the ASND short interest.
ASND Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ASND. When comparing the yearly performance of all stocks, ASND turns out to be only a medium performer in the overall market: it outperformed 67.97% of all stocks.
ASND Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ASND. ASND has a bad profitability rating. Also its financial health evaluation is rather negative.
ASND Financial Highlights
Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -6.88. The EPS increased by 23.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ASND Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ASND. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 40.97% and a revenue growth 79.11% for ASND